Navigation Links
Imprimis Pharmaceuticals, Inc. Acquires Intellectual Property Assets from Buderer Drug Company
Date:6/17/2013

SAN DIEGO, Calif., June 17, 2013 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY) today announced it has completed the acquisition of intellectual property (IP) rights related to certain proprietary innovations from the compounding pharmacy operations of Ohio-based Buderer Drug Company. The acquisition allows Imprimis to pursue the commercial development of these proprietary innovations and also provides Imprimis with a right of first refusal on additional Buderer Drug Company intellectual property and drug development opportunities.

Buderer Drug Company, which has served the needs of patients and physicians in Ohio since 1878, is a compounding pharmacy member of PCCA. This IP acquisition is the first to emerge from the Imprimis-PCCA relationship.

"Buderer Drug Company is a leading compounding pharmacy organization in the United States, and we are extremely pleased to announce this asset purchase," said Mark L. Baum, Imprimis CEO. "This new relationship, which could lead to up to three new development programs, is a good example of our plan to begin to leverage our agreement with PCCA into proprietary IP that may ultimately lead to the FDA approval of new medicines to address unmet patient needs. We are in the process of preparing filings with the USPTO related to the acquired assets and intend to communicate with the marketplace with more specificity in the near-term. Ultimately, we intend to develop and commercialize any drug development assets we decide to pursue by utilizing the U.S. Food and Drug Administration (FDA) 505(b)(2) regulatory pathway. The 505(b)(2) pathway has the ability to significantly reduce both cost and duration of the FDA approval process, bringing quality medications more quickly to patients who
'/>"/>

SOURCE Imprimis Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Imprimis Pharmaceuticals, Inc. to Present at the National Investment Banking Association (NIBA) Conference June 18th in New York City
2. Imprimis Pharmaceuticals Announces Underwriter Exercise of Over-Allotment Option
3. Imprimis Pharmaceuticals Out Licenses Its Proprietary IP to resolutionMD for Cosmeceutical Products
4. Imprimis Announces Key Leadership Appointments
5. Imprimis Announces Successful Results from its Pharmacokinetic Study for its Impracor Topical NSAID
6. Imprimis Pharmaceuticals Announces Pricing of Public Offering of 1,840,000 Shares of Common Stock
7. Imprimis to Begin New Study of Its Topical Analgesic Drug
8. Imprimis Names Two Experts To Its Science And Regulatory Board
9. Imprimis Pharmaceuticals Signs Agreement With DPT Labs For Clinical Supplies In Advance Of Planned Phase 3 Studies For Its Ketoprofen-Based Topical Anti-Inflammatory Drug
10. Dr. Gerald Yakatan Joins Imprimis Pharmaceuticals Science and Regulatory Advisory Board
11. Stephen G. Austin, CPA Joins Imprimis Pharmaceuticals Board Of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Mass. , Jan. 15, 2014  Zafgen, Inc., ... unmet needs of severely obese patients, today announced ... beloranib, a selective inhibitor of methionine aminopeptidase 2 ... severe form of genetic obesity.  These results showed ...
(Date:1/14/2014)...  Luminex Corporation (Nasdaq: LMNX ) today announced that ... 2013 on Monday, February 3, 2014. A press release announcing ... trading. (Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO ) ... highlights and financial results for the fourth quarter and twelve ...
(Date:1/14/2014)... Dynamic Healthcare Services, Inc. ("DHS"), a portfolio company of GMH ... Medical Equipment, Inc. ("Progressive") of Clarion, PA ... were not disclosed. Progressive is a full ... of sleep, mobility, and respiratory products to customers in the ...
Breaking Medicine Technology:Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 3
... Solutions LLC today announced the launch of their ... a minimally invasive, Board Certified, OB/GYN surgeon Dr. ... improve patient and surgical team safety.  This proprietary device ... and reload sutures with an efficient, one-handed motion resulting ...
... (Nasdaq: BMRN ) announced today that the ... study (PKU-016) to evaluate the effects of Kuvan (sapropterin ...  BioMarin expects to report results in the first half ... will provide quantitative data regarding the neuropsychiatric effects of ...
Cached Medicine Technology:Equinox Surgical Solutions Launches Flagship Product, SutureAssist® 2BioMarin Initiates Phase 3b Study to Evaluate the Effects of Kuvan on Neurophychiatric Symptoms in Subjects with PKU 2BioMarin Initiates Phase 3b Study to Evaluate the Effects of Kuvan on Neurophychiatric Symptoms in Subjects with PKU 3
(Date:4/17/2014)... (April 17, 2014) Two recent papers by ... and colleagues may help scientists develop treatments or ... fever, Japanese encephalitis and other disease-causing flaviviruses. , ... and molecular genetics at the School of Medicine ... Hughes Medical Institute, and colleagues recently published articles ...
(Date:4/17/2014)... Jon McCullers, MD, was recently invited to submit ... Nature Reviews Microbiology , one of the world,s ... infectious disease specialist, and chair of the Department ... Science Center, analyzed the epidemiology and microbiology of ... as well as more recent 2009 novel H1N1 ...
(Date:4/17/2014)... April 17, 2014U.S. military personnel who served in ... concussive traumatic brain injury (TBI) were compared to ... other medical reasons. Differences in measures of overall ... months after injury are reported in an article ... journal from Mary Ann Liebert, Inc., publishers. The ...
(Date:4/17/2014)... that as many as 10 million older Americans suffer ... and isolation. , However, new research a project ... Americans for six years found that Internet use ... by more than 30 percent. , "That,s a very ... professor of telecommunication, information studies and media who led ...
(Date:4/17/2014)... CHICAGO, IL, April 17, 2014-- Colic affects about one ... accounts for numerous pediatric visits during the first several ... of colic symptoms was showing promise; however, the April ... (BMJ2014;348:g2107; Sung, Valerie) reported on a study, "Probiotics ... probiotic L reuteri for infant colic ...
Breaking Medicine News(10 mins):Health News:CU researchers discover target for treating dengue fever 2Health News:Long-term effects of battle-related 'blast plus impact' concussive TBI in US military 2Health News:Internet use can help ward off depression among elderly 2Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2
... that 2.5 percent of the United States population, or about ... found to be higher for children, non-Hispanic blacks, and males, ... having food allergies were 4.4 times higher than others in ... by the National Institutes of Health and appears in the ...
... percent) of 11- to 13-year-old babysitters know who to contact ... is sick or injured (96 percent) or poisoned (85 percent), ... Academy of Pediatrics (AAP) National Conference and Exhibition in San ... had left children unattended while babysitting, and 20 percent opened ...
... Serena Gordon HealthDay Reporter , FRIDAY, Oct. 1 ... be more likely to recommend healthy lifestyle habits to their ... of times a week and rarely hit the gym, according ... experienced doctors and those who felt they,d been well-trained to ...
... than two hours per week reduces the risk of developing ... to women of the same race who do not exercise, ... Results were presented at the Third AACR Conference on The ... 3, 2010. "People often want to know ...
... out of lung CT scans to improve treatment of ... has earned a physician-scientist at The University of Texas ... the National Institutes of Health. The award, one ... $1.5 million over five years to Thomas Guerrero, M.D., ...
... (CAD) is increasing, in both screening and diagnostic mammography, according ... of the American College of Radiology ( www.jacr.org ). CAD ... of density, mass or calcification on a digitized mammographic image ... Screening mammography is an X-ray exam of ...
Cached Medicine News:Health News:Children, males and blacks are at increased risk for food allergies 2Health News:Doctors' Health, Well-Being Affect Patient Counseling 2Health News:Doctors' Health, Well-Being Affect Patient Counseling 3Health News:Vigorous exercise reduces breast cancer risk in African-American women 2Health News:NIH award goes to UT MD Anderson imaging innovator Guerrero 2Health News:NIH award goes to UT MD Anderson imaging innovator Guerrero 3Health News:Computer-aided detection is increasingly being used in screening and diagnostic mammography 2
Curved shafts with fine pointed tips. Smooth handle with dull finish....
Delicate curved shafts with light crisscross serrations. Serrated handle with polished finish. Most popular size or model....
Delicate cross serrated lightly curved tips with serrated handle and polished finish. Most popular size or model....
Delicate lightly curved tips, 1 x 2 mouse style teeth. Serrated handle with polished finish....
Medicine Products: